A Study of Baricitinib (LY3009104) in Adult and Pediatric Japanese Participants With NNS/CANDLE, SAVI, and AGS

NCT04517253 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

TERMINATED

Status

10

Enrollment

INDUSTRY

Sponsor class

Stopped The study was terminated due to efficacy/effectiveness reasons

Conditions

Nakajo-Nishimura Syndrome
Chronic Atypical Neutrophilic Dermatosis With Lipodystrophy and Elevated Temperature Syndrome
STING-Associated Vasculopathy With Onset in Infancy
Aicardi Goutieres Syndrome

Interventions

DRUG: Baricitinib

Sponsor

Eli Lilly and Company